Lana Xian Tong, MD
Dermatology · Burlingame
- Medicare standing
- 2 flags on the record
- Listed below.
- Plans that list them
- 9
- 1 carrier
- Offices
- 3
On the public record
- California licence: Accusation Filed
- 1 Medical Board action on record
Offices
3 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Looking this up.
Hospitals listed: Mills-Peninsula Medical Center. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Tong’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A162330 · Current
Licensed to practise in California · since 2019 · expires 2027-05-31 · David Geffen School of Medicine at UCLA. Board flags: Accusation Filed.
Public record actions
| 2026-04-09 | Board disciplineDiscipline | Accusation filed. the physician has not had a hearing or been found guilty of any charges. · 8002024113825 |
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
See every measure and the patient survey for Peninsula Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.139 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.242 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.21 (0.27 to 2.15) · 1,258 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.51 to 1.1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 155.44 (112.67 to 198.21) · 90 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 32 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 188 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9 · 473 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 342 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 485 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 3,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 6,904 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,052 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (1.43 to 5.39) · 1,695 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.72 (0.17 to 3.28) · 665 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,545 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.1 (1.3 to 12.9) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.96 (2.63 to 9.29) · 653 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 418 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 5,539 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 192 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.215 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.263 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.74 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 300 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.2 · 207 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.6 · 531 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.3 · 343 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 449 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.5 (2.8 to 7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.6 (6.7 to 13.7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11 · 45 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 117 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17.2) · 584 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 764 cases | No different | Jan 2024 – Dec 2024 |
What patients said (523 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$105,471
Medicare paid this office $105,471 for 285 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 212 | $37,857 | $102 |
| Destruction of precancer skin growth, 15 or more growths | 65 | $16,197 | $157 |
| Destruction of skin growth, 1-14 growths | 96 | $13,340 | $107 |
| New patient visit (45+ min) | 78 | $8,970 | $115 |
| Destruction of precancer skin growth, 1 growth | 115 | $6,991 | $46 |
See all 9 services
| Return visit (30+ min) | 212 | $37,857 | $102 |
| Destruction of precancer skin growth, 15 or more growths | 65 | $16,197 | $157 |
| Destruction of skin growth, 1-14 growths | 96 | $13,340 | $107 |
| New patient visit (45+ min) | 78 | $8,970 | $115 |
| Destruction of precancer skin growth, 1 growth | 115 | $6,991 | $46 |
| Biopsy of related skin growth, first growth | 46 | $4,347 | $82 |
| Destruction of precancer skin growth, 2-14 growths | 100 | $2,740 | $7 |
| Punch biopsy, first skin growth | 14 | $1,777 | $127 |
| Biopsy of related skin growth, each additional growth | 13 | $1,317 | $49 |
Procedures Medicare counted
| Removal of skin lesions | 418 | More than 85% of doctors who do this |
| Removal or shaving of skin growth | 12 | More than 66% of doctors who do this |
| Skin biopsy | 76 | More than 73% of doctors who do this |
Who their Medicare patients are
285 Original Medicare patients in 2024. Average age 75 · Women 66% · Also on Medicaid 5% · Health risk score 1.00. At or below the middle of the specialty; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 65% · Diabetes 21% · Coronary heart disease 21% · Chronic kidney disease 19% · Cancer 19% · Atrial fibrillation 16% · Heart failure 11% · COPD 10% · Depression 10% · Dementia 4%.
The office billed $403,522, Medicare allowed $150,040 and paid $105,471; for 1,389 services of 35 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 285 | 1,389 | 75 | 1.00 | $403,522 | $105,471 |
| 2023 | 336 | 1,784 | 75 | 0.93 | $488,350 | $138,613 |
| 2022 | 381 | 1,979 | 74 | 0.91 | $627,567 | $171,252 |
| 2021 | 286 | 1,330 | 75 | 0.89 | $378,039 | $111,304 |
| 2020 | 228 | 834 | 74 | 1.08 | $197,505 | $55,574 |
| 2019 | 65 | 162 | 77 | 1.17 | $42,437 | $11,977 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 11 services
| Return visit (30+ min) | 235 | $38,835 | $107 |
| Destruction of skin growth, 1-14 growths | 137 | $19,824 | $107 |
| Destruction of precancer skin growth, 15 or more growths | 61 | $19,746 | $169 |
| New patient visit (45+ min) | 100 | $12,732 | $127 |
| Destruction of precancer skin growth, 1 growth | 149 | $9,622 | $47 |
| Biopsy of related skin growth, first growth | 41 | $4,734 | $75 |
| Destruction of precancer skin growth, 2-14 growths | 125 | $3,664 | $7 |
| Short return visit (20+ min) | 33 | $2,579 | $70 |
| Punch biopsy, first skin growth | 15 | $2,114 | $124 |
| Shaving of skin growth of body, arms, or legs, 0.6-1.0 cm | 18 | $2,056 | $108 |
| New patient visit (30+ min) | 17 | $1,504 | $88 |
2022: 13 services
| Return visit (30+ min) | 235 | $38,734 | $106 |
| Destruction of skin growth, 1-14 growths | 143 | $18,251 | $103 |
| New patient visit (45+ min) | 128 | $15,601 | $122 |
| Destruction of precancer skin growth, 15 or more growths | 51 | $14,801 | $163 |
| Destruction of precancer skin growth, 1 growth | 172 | $9,775 | $41 |
| Destruction of skin growth, 15 or more growths | 43 | $8,357 | $121 |
| Biopsy of related skin growth, first growth | 76 | $7,284 | $77 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 19 | $6,260 | $285 |
| Short return visit (20+ min) | 40 | $3,171 | $65 |
| Punch biopsy, first skin growth | 23 | $3,038 | $122 |
| Destruction of precancer skin growth, 2-14 growths | 145 | $3,028 | $7 |
| New patient visit (30+ min) | 34 | $2,863 | $84 |
| Biopsy of related skin growth, each additional growth | 19 | $1,262 | $53 |
2021: 12 services
| Return visit (30+ min) | 136 | $22,869 | $112 |
| Destruction of skin growth, 1-14 growths | 94 | $13,714 | $105 |
| Destruction of precancer skin growth, 1 growth | 115 | $8,275 | $48 |
| New patient visit (45+ min) | 62 | $8,222 | $133 |
| Short return visit (20+ min) | 84 | $7,449 | $77 |
| Destruction of precancer skin growth, 15 or more growths | 15 | $3,638 | $165 |
| Biopsy of related skin growth, first growth | 30 | $3,269 | $86 |
| New patient visit (30+ min) | 33 | $2,686 | $81 |
| Destruction of precancer skin growth, 2-14 growths | 90 | $2,059 | $7 |
| Punch biopsy, first skin growth | 15 | $1,951 | $122 |
| Short return visit | 26 | $1,391 | $45 |
| Biopsy of related skin growth, each additional growth | 11 | $708 | $51 |
2020: 10 services
| Destruction of skin growth, 1-14 growths | 52 | $9,301 | $106 |
| Return visit (30+ min) | 84 | $7,975 | $83 |
| Short return visit (20+ min) | 98 | $7,493 | $62 |
| Destruction of precancer skin growth, 1 growth | 75 | $5,768 | $48 |
| New patient visit (30+ min) | 43 | $3,305 | $77 |
| Biopsy of related skin growth, first growth | 36 | $3,157 | $81 |
| New patient visit (15+ min) | 38 | $2,381 | $63 |
| Punch biopsy, first skin growth | 11 | $1,408 | $128 |
| Destruction of precancer skin growth, 2-14 growths | 55 | $1,044 | $6 |
| Biopsy of related skin growth, each additional growth | 11 | $694 | $53 |
2019: 7 services
| New patient visit (30+ min) | 24 | $2,314 | $96 |
| Destruction of skin growth, 1-14 growths | 14 | $1,536 | $110 |
| Return visit (30+ min) | 14 | $1,515 | $101 |
| Biopsy of related skin growth, first growth | 16 | $1,367 | $85 |
| Destruction of precancer skin growth, 1 growth | 21 | $1,227 | $49 |
| New patient visit (15+ min) | 19 | $1,158 | $61 |
| Destruction of precancer skin growth, 2-14 growths | 15 | $131 | $5 |
Medicaid work
$3,928 in 2024
Medicaid paid $3,928 for 42 billed services this clinician did in 2024, up to 15 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 42 | $3,928 |
| 2024 | 42 | 1 | 15 | $3,928 |
| 2022 | 82 | 1 | 15 | $2,046 |
See the largest Medicaid services in earlier years
2022
| Return visit (30+ min) | 82 | $2,046 |
Drugs they prescribed that Part D paid
$78,079
Pharmacies billed $78,079 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 883) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.
844 generic and 39 brand-name prescriptions · $78,079 in drug cost · 41 antibiotic prescriptions to 21 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Dupixent | 12 | $46,022 | $3,835 |
| Metronidazole | 96 | $4,632 | $48 |
| Ketoconazole | 279 | $4,399 | $16 |
| Clobetasol Propionate | 54 | $4,036 | $75 |
| Sulfacetamide | 17 | $1,895 | $111 |
See all 14 drugs
| Dupixent | 12 | $46,022 | $3,835 |
| Metronidazole | 96 | $4,632 | $48 |
| Ketoconazole | 279 | $4,399 | $16 |
| Clobetasol Propionate | 54 | $4,036 | $75 |
| Sulfacetamide | 17 | $1,895 | $111 |
| Ciclopirox | 40 | $1,494 | $37 |
| Fluocinonide | 27 | $983 | $36 |
| Fluocinolone Acetonide | 25 | $960 | $38 |
| Triamcinolone Acetonide | 88 | $927 | $11 |
| Clindamycin Phosphate | 21 | $798 | $38 |
| Econazole Nitrate | 23 | $728 | $32 |
| Clindamycin-Benzoyl Peroxide | 11 | $692 | $63 |
| Doxycycline Hyclate | 23 | $380 | $17 |
| Hydrocortisone | 30 | $187 | $6 |
Year by year
| 2024 | 883 | 349 | 0% (0) | 4% | $78,079 |
| 2023 | 838 | 344 | 0% (0) | 8% | $196,372 |
| 2022 | 866 | 390 | 0% (0) | 8% | $88,057 |
| 2021 | 563 | 234 | 0% (0) | 7% | $30,537 |
| 2020 | 291 | 137 | 0% (0) | 9% | $17,480 |
| 2019 | 115 | 68 | 0% (0) | 12% | $30,098 |
| 2018 | 299 | 91 | 0% (0) | 10% | $69,429 |
| 2017 | 199 | 61 | 0% (0) | None | $15,860 |
| 2016 | 182 | 82 | 0% (0) | 14% | $27,269 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 15 drugs
| Clobetasol Propionate | 85 | $8,878 | $104 |
| Ketoconazole | 282 | $6,219 | $22 |
| Tacrolimus | 11 | $3,046 | $277 |
| Metronidazole | 54 | $3,017 | $56 |
| Sulfacetamide | 26 | $3,001 | $115 |
| Fluocinonide | 43 | $2,605 | $61 |
| Fluocinolone Acetonide | 28 | $2,064 | $74 |
| Doxycycline Hyclate | 30 | $1,005 | $33 |
| Ciclopirox | 27 | $929 | $34 |
| Desonide | 14 | $680 | $49 |
| Triamcinolone Acetonide | 82 | $595 | $7 |
| Clindamycin Phosphate | 11 | $386 | $35 |
| Mometasone Furoate | 12 | $331 | $28 |
| Hydrocortisone | 24 | $210 | $9 |
| Mupirocin | 16 | $198 | $12 |
2022: 13 drugs
| Metronidazole | 99 | $7,162 | $72 |
| Ketoconazole | 266 | $6,691 | $25 |
| Clobetasol Propionate | 81 | $5,927 | $73 |
| Fluocinonide | 54 | $3,536 | $65 |
| Azelaic Acid | 12 | $1,862 | $155 |
| Halobetasol Propionate | 22 | $1,555 | $71 |
| Fluocinolone Acetonide | 29 | $1,526 | $53 |
| Doxycycline Hyclate | 28 | $1,062 | $38 |
| Triamcinolone Acetonide | 72 | $638 | $9 |
| Minocycline | 12 | $436 | $36 |
| Hydroxyzine | 11 | $363 | $33 |
| Hydrocortisone | 30 | $278 | $9 |
| Mupirocin | 12 | $90 | $8 |
2021: 12 drugs
| Fluocinonide | 71 | $4,727 | $67 |
| Clobetasol Propionate | 84 | $4,237 | $50 |
| Ketoconazole | 109 | $2,531 | $23 |
| Metronidazole | 26 | $1,997 | $77 |
| Halobetasol Propionate | 13 | $1,045 | $80 |
| Doxycycline Hyclate | 23 | $773 | $34 |
| Fluocinolone Acetonide | 17 | $763 | $45 |
| Triamcinolone Acetonide | 51 | $587 | $12 |
| Econazole Nitrate | 12 | $421 | $35 |
| Hydrocortisone | 31 | $262 | $8 |
| Mupirocin | 24 | $249 | $10 |
| Hydroxyzine | 14 | $235 | $17 |
2020: 9 drugs
| Clobetasol Propionate | 43 | $5,185 | $121 |
| Fluorouracil | 18 | $1,546 | $86 |
| Fluocinonide | 21 | $1,023 | $49 |
| Fluocinolone Acetonide | 14 | $866 | $62 |
| Ketoconazole | 26 | $496 | $19 |
| Doxycycline Hyclate | 15 | $412 | $27 |
| Triamcinolone Acetonide | 41 | $290 | $7 |
| Hydrocortisone | 18 | $166 | $9 |
| Hydroxyzine | 15 | $163 | $11 |
2019: 2 drugs
| Clobetasol Propionate | 15 | $1,358 | $91 |
| Triamcinolone Acetonide | 18 | $210 | $12 |
2018: 8 drugs
| Clobetasol Propionate | 27 | $2,755 | $102 |
| Halobetasol Propionate | 16 | $2,533 | $158 |
| Triamcinolone Acetonide | 47 | $1,356 | $29 |
| Clindamycin Phosphate | 11 | $448 | $41 |
| Ketoconazole | 19 | $425 | $22 |
| Ammonium Lactate | 12 | $300 | $25 |
| Hydrocortisone | 19 | $209 | $11 |
| Mupirocin | 14 | $178 | $13 |
2017: 8 drugs
| Fluocinolone Acetonide | 16 | $3,437 | $215 |
| Clobetasol Propionate | 16 | $2,572 | $161 |
| Clindamycin Phosphate | 13 | $1,281 | $99 |
| Triamcinolone Acetonide | 36 | $650 | $18 |
| Betamethasone Valerate | 11 | $519 | $47 |
| Ketoconazole | 19 | $245 | $13 |
| Valacyclovir | 12 | $228 | $19 |
| Hydrocortisone | 11 | $76 | $7 |
2016: 5 drugs
| Clobetasol Propionate | 37 | $7,033 | $190 |
| Econazole Nitrate | 11 | $2,976 | $271 |
| Ketoconazole | 14 | $360 | $26 |
| Triamcinolone Acetonide | 22 | $349 | $16 |
| Mupirocin | 11 | $85 | $8 |
Money from drug and device companies
$269 in 2025
| 2025 | 7 | 13 | None | $269 |
| 2023 | 1 | 1 | None | $15 |
| 2021 | 2 | 6 | None | $214 |
| 2020 | 2 | 6 | None | $148 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Arcutis Biotherapeutics | Zoryve | $97 | 6 payments
|
| Janssen Biotech | Tremfya | $46 | 2 payments
|
| Lilly USA | Taltz | $32 | 1 payment
|
| Galderma Laboratories L.P. | Nemluvio | $26 | 1 payment
|
| Botanix SB | Sofdra | $25 | 1 payment
|
| Amgen | Otezla | $24 | 1 payment
|
See all 13 published payments
| Cipher Pharmaceuticals US | Meals · 2025-12-01 | Natroba | $19 |
| Arcutis Biotherapeutics | Meals · 2025-12-01 | Zoryve | $14 |
| Botanix SB | Meals · 2025-11-11 | Sofdra | $25 |
| Arcutis Biotherapeutics | Meals · 2025-10-23 | Zoryve | $22 |
| Arcutis Biotherapeutics | Meals · 2025-10-22 | Zoryve | $18 |
| Janssen Biotech | Meals · 2025-10-13 | Tremfya | $15 |
| Amgen | Meals · 2025-10-06 | Otezla | $24 |
| Arcutis Biotherapeutics | Meals · 2025-08-19 | Zoryve | $14 |
| Lilly USA | Meals · 2025-08-18 | Taltz | $32 |
| Galderma Laboratories L.P. | Meals · 2025-08-01 | Nemluvio | $26 |
| Arcutis Biotherapeutics | Meals · 2025-07-14 | Zoryve | $14 |
| Arcutis Biotherapeutics | Meals · 2025-07-14 | Zoryve | $14 |
| Janssen Biotech | Meals · 2025-07-11 | Tremfya | $31 |
See earlier years (2023, 2021, 2020)
2023: $15
| Pfizer | Cibinqo | $15 | 1 payment
|
2021: $214
| Regeneron Healthcare Solutions | Dupixent | $131 | 3 payments
|
| AbbVie | Skyrizi | $83 | 3 payments
|
2020: $148
| Regeneron Healthcare Solutions | Dupixent | $86 | 3 payments
|
| AbbVie | Skyrizi | $61 | 3 payments
|
Professional record
- NPI
- 1386022176
- Licence
- CA A162330California A162330: Current · expires 2027-05-31
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207N00000X (207N00000X); Student in a training program (390200000X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2015-05-12
- NPI last updated
- 2020-06-23
- NPI record certified
- 2020-06-23
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 751 S Bascom Ave, San Jose, CA, 95128